Skip to content
Q1 '26Q4 '25Q3 '25Q2 '25Q1 '25
-$23.52M-15.8%-$20.77M-29.1%-$21.53M-23.2%-$21.25M-19.1%-$20.31M-45.5%
$666K+6.1%$666K+8.5%$662K+5.6%$641K+6.3%$628K+7.0%
$1.59M-22.4%$1.59M-27.2%$1.63M-14.5%$1.55M+4.5%$2.05M+45.9%
-$20.95M-5.6%-$14.73M-0.5%-$19.2M-65.4%-$22.98M-67.9%-$19.84M-31.5%
$242K-52.6%$421K+558%$600K+525%$1.06M+127%$511K+2,739%
$15.32M+53.6%$16.04M+1,760%$16.28M+112%$21.12M+1,466%$9.97M+1.9%
-$112K-147%$239K
-$5.75M+40.3%$0+100%-$2.96M-114%-$1.93M+86.1%-$9.63M-81.6%
-$21.19M-4.1%-$15.15M-2.9%-$19.8M-69.1%-$24.04M-69.9%-$20.35M-34.7%

Chart any of these lines over time, or line them up against competitors.

Compare these in charts →

Questions, answered.

How much cash does Artiva Biotherapeutics, Inc. generate?
Artiva Biotherapeutics, Inc. (ARTV) generated -$77.9M in operating cash flow over the trailing twelve months.
What is Artiva Biotherapeutics, Inc.'s free cash flow?
After $2.3M of capital expenditures, Artiva Biotherapeutics, Inc.'s free cash flow was -$80.2M over the trailing twelve months, down 31.6% year over year.
Where does Artiva Biotherapeutics, Inc.'s cash flow data come from?
Every line is extracted from Artiva Biotherapeutics, Inc.'s SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.